KOLESTEROL İLAÇLARI AKIL VE MANTIĞA AYKIRIDIR

Yazı Fontunu Büyült Yazı Fontunu Küçült Yazı Fontunu Sıfırla
akıl ve mantık

Dikkat: Yazının sonunda ek var!

***

Hazır çorbalara para karşılığı “kalp dostu” logosu vermekle ünlenen, sahtekârlıkla suçlanan Amerikan Kalp Derneği’ nin yeni “kolesterol hapını yutturma kılavuzu” ilaç endüstrisine milyarlarca dolar kazandırmanın yolunu açıyor.

Bu yeni yutturma kılavuzuna göre, ortada herhangi bir “kalp hastalığı salgını” ve kolesterolü düşürmenin faydalı olduğunu gösteren bir veri yokken bugünküne göre en az iki misli insan kolesterol hapı kullanmaya başlayacak.

Bu zamana kadar satışlar “kötü kolesterol seviyelerinin her geçen gün aşağı çekilmesiyle” pompalanmaya çalışıldı; bundan sonra insanlar “düşük risk” tehdidiyle korkutulacak.

Önceki kılavuzunda riskleri yüzde 10-20 arasında olanlara yazılan haplar bundan böyle 10 senedeki riski 7.5 olanlara da yutturulacak.

John D. Abramson ve Rita F. Redberg New York Times’ ta şunları yazıyorlar:

“BMJ’ de yeni yayınlanan bir makaleye göre kalp hastalığı riski yüzde 20’ den düşük olanlara kolesterol hapı (statin) verilmesi ölüm riskini azaltmıyor ve tek bir kalp krizi veya felci önlemek için 140 insana statin verilmesi icap ediyor.

Tedaviye başlarken bu 140 kişiden kimin korunacağı bilinmediği gibi kalan 139 kişi ilacı hem boşuna almış oluyor hem de bunların yüzde 18’ i kas ağrısı, hafıza kaybı, diyabet, katarakt ve iktidarsızlık gibi yan etkilere de maruz kalıyor.

2001’ de yayınlanan “yutturma kılavuzu” ile kolesterol hapı tavsiye edilen Amerikalıların sayısı bir anda 13 milyondan 36 milyona çıkmıştı.

Üstelik de o kılavuzun klinik araştırmaların sonuçlarına dayanılarak hazırlandığı bildirilmiş olmasına karşılık kılavuzda tanımlanan dokümanlar bunu doğrulamıyordu.

LDL’ yi daha fazla düşürmenin bir işe yaradığını gösteren yeterli delil olmadığı için de yeni yutturma kılavuzunda bundan hiç bahsedilmiyor.

Aslında komite üyeleri kolesterolü ilaçlarla düşürmek ile beslenme, egzersiz gibi ilaçsız yöntemlerle düşürmenin etkilerinin aynı olmadığını biliyorlar”.

Ayrıca, yutturma kılavuzunda görev alanların ilaç endüstrisi ile çıkar ilişkileri olduğu gibi hem “çorbacı AHA” hem American College of Cardiology kâr amacı gütmeyen kuruluşlar ama ilaç firmaları tarafından destekleniyorlar.

Kılavuzu AHA olanın burnu…

Yıllardır söylüyorum, bir daha tekrarlayayım: Kolesterol teorisi bir “pazarlama numarasıdır”.

Ateroskleroz yani damar sertliği bir “kolesterol depolanması hastalığı değil, kronik bir enflamasyon yani mikropsuz iltihaptır”.

Kalp krizi geçirenlerin yarının kolesterol seviyeleri normaldir; kolesterolü yüksek olanın da düşük olanın da aynı riske sahip olması zaten mantık dışıdır.

Kolesterol yüksekliğinin aterosklerozun sebebi değil, diyabet, obezite, hipertansiyon, hatalı beslenme, hareketsizlik, sigara-alkol, stres gibi etkenlerin sonucu olarak ortaya çıkması mümkündür.

Doğru beslenme, düzenli egzersiz, sigarayı bırakma ile kolesterolü düşmesi de bunun ispatıdır.

Şimdi rahmetle andığım aziz dostum, değerli bilim adamı biyolog Mevlüt Durmuş’ un “kolesterol yüksekliğinin fazla yapımdan değil kolesterolün kanda birikmesinden kaynaklandığını” iddia eden teorisini de çok mantıklı buluyorum.

Birazcık aklı olanlar, statinlerin kolesterol sentezini azalttıkları için değil anti-enflamatuar etkilerinden dolayı işe yarayabileceğini görüyorlar ama bunu söylemeye dilleri varmıyor.

Çünkü insanların beynini senelerce “Kolesterol yüksekliği bir hastalıktır; ateroskleroz ve kalp krizinin sebebi yüksek kolesteroldür” diye yıkadıkları için tükürdüklerini yalamak zorunda kalacaklar.

Gelelim neticeye

BİR: Aterosklerozun fizyo-patolojisini, statinlerin etki mekanizmasını, aksi tesirlerini, mutlak faydasının azlığını dikkate aldığımızda statin sınıfı ilaç yazmak akıl ve mantığa aykırıdır.

İKİ: Ben kolesterol değerlerimi bilmiyorum, bilsem de benim için değişen hiçbir şey olmayacak.

Kalp-damar hastalıklarından korunmak için yapılması gerekenler sağlıklı beslenmek, düzenli hareketlilik ve sigara kullanmamaktır.

KAYNAKLAR

http://www.bmj.com/content/347/bmj.f6123

http://www.nytimes.com/2013/11/14/opinion/dont-give-more-patients-statins.html?_r=0

http://www.ahmetrasimkucukusta.com/2012/01/11/yazilar/tip-yazilari/kolesterol/olesterol-ilaclarina-neden-guvenmiyorum/

***

EK 1 (2.8.2023): Are medical journals dead?

Problems that have plagued medical journals for decades include the failure of peer review, replication crisis, ghost-writing, and the influence of Big Pharma.

In 2004, Richard Horton, editor of the Lancet wrote, “Journals have devolved into information laundering operations for the pharmaceutical industry.”

More recently, Peter Gøtzsche, one of the founding fathers of the Cochrane Collaboration said, “The medical publishing system is broken. It doesn’t ensure that solid research which goes against financial interests can get published without any major obstacles.”

Scientific publishing is now one of the most profitable businesses. Elsevier, for example, made$2.9 billion in annual revenue with a profit margin approaching 40%, rivalling that of Apple and Google.

But despite these impressive numbers, trust in medical journals has diminished, and this has only been exacerbated by the covid-19 pandemic. 

Peer review fail

Former editor of The BMJ Richard Smith once famously wrote; “Peer review is faith not evidence based, but most scientists believe in it as some people believe in the Loch Ness monster.”

In a recent conversation with Richard Smith, he explained why.

   

Richard Smith, former editor of The BMJ

“Peer review was thought to be at the heart of science – that is, who gets a grant or who gets a Nobel Prize – and I suppose it wasn’t until the 80s and 90s that somebody actually examined it – it was just sort of assumed to be a good thing,” said Smith.

“Then people began a series of experiments – there was a Cochrane review – looking at the evidence to see if peer-review was beneficial. And actually, what they found was that there was really no evidence,” he said.

Smith, who worked at The BMJ for 25 years said the peer-review process is slow, it’s expensive, and it stifles the publication of innovative ideas.

“There are lots of examples of ground-breaking work that were rejected by peer-reviewers but go on to win Nobel Prizes. Is the work crazy? Or is it truly genius? Peer review is not good at deciding that,” he said.

Peer review also fails to detect fraud. The recent Surgisphere scandal is a case in point.

Lancet and New England Journal of Medicine were forced to retract studies after researchers reported a link between treatment with hydroxychloroquine and increased death of hospitalised covid patients.

Glaring discrepancies were found in the database underpinning the studies, but were not detected in the peer-review process.

“If researchers say there were 200 patients in the study, then you assume there were. But we have increasing evidence that that’s not the case – there are a lot of zombie trials that never happened or have been manipulated in some way,” said Smith.

“So, in a nutshell, we have lots and lots of evidence of the downside of peer review and really no convincing evidence of its upside,” he added.

Rita Redberg, a cardiologist at the University of California San Francisco, who recently stepped down after 14 years as chief editor of JAMA Internal Medicine, concedes that peer-review is “not perfect”. 

   

Rita Redberg, cardiologist, former chief editor of JAMA Internal Medicine

“You always assume that what the authors are telling you is true. The process depends on the honesty of the authors, and yes, people can be dishonest.  But we’re doctors, we’re not investigators with the resources of the FBI. Of course, when any potential dishonesty comes to our attention, we will investigate,” said Redberg.

“It has its problems, but what’s the alternative?  No peer-review? In general, I think peer review is much better than a system without peer review,” added Redberg.

Politicisation of journals

During the pandemic, some journal editors became increasingly politicised. 

Editors at the New England Journal of Medicine, for example, took the rare step of writing an editorial in 2020, urging American voters to oust the sitting President. It was a controversial move.

John Ioannidis, Professor of Medicine at Stanford University, and the most cited scientist in the world, said he is not in favour of the politicisation of medical journals.

“The message it sends is that scientific journals are just another arm of the political propaganda machine,” said Ioannidis.

   

John Ioannidis, Professor of Medicine, Stanford University

“That’s not to say that scientific journals shouldn’t take stances on important issues that are decided by politicians like climate change, regulation of industry, and environmental pollution. I just think the editorials were very poor choices and not for the pages of the journals,” he said.

Ioannidis is not convinced that these political statements swayed anyone to cross the political aisle, and thinks the editorials should be retracted.

“To be honest, the editors who made these statements should retract their own editorials on these political issues. Editors can keep their political orientation and still cover all the big important medical issues,” he added.

Emergence of pre-prints

Pre-prints are non-peer-reviewed articles posted on servers such as medRxiv and bioRxiv, that allow thousands of people to view the research. Many see this as a double-edged sword.

It enables faster data sharing in an emergency and quick feedback, but it also opens the door to sloppy science that can be widely disseminated by the public and the media.

Redberg’s personal view is that pre-prints, which have not undergone peer-review, are potentially harmful. 

“I think there’s a danger of putting out information that’s not accurate. For approval of drugs and devices, it’s worth taking the time to get things right. I feel much more confident that you’re going to get it right if it’s undergone peer review,” said Redberg.

“I think it started with very good intentions – people sharing their work and getting comments – but the articles stay up there even after they’re published in journals, and having an older, different–and possibly inaccurate–version remaining in the public sphere may inadvertently disseminate incorrect information,” added Redberg.

Ioannidis, on the other hand, says he is in favour of pre-prints because “they offer more transparency in the system, and they allow for some earlier dissemination of work,”.

But he warned it can be a battlefield citing experiences where some of his pre-prints would receive more than 1000 peer reviews within a day of release. 

“A few were very, very helpful. Hundreds of them were just abuse. It was a very traumatic experience. If you separate what is the good contribution versus the abuse, then I think that they’re useful,” said Ioannidis.

Smith argues that pre-prints actually prove his point about the failure of peer-review. “If you look at what eventually appears in journals, it’s usually very similar to the original pre-print. So, it’s evidence that peer review has not made much of a difference,” said Smith.

“What I argue is that the peer review should not be three or four selected people looking at something before it’s published, but where the ideas are available to everybody. That’s the real peer review,” he said.

Scientific censorship

Publishing articles in medical journals during the pandemic, especially research that was critical of vaccine safety, was sometimes censored or retracted for no good reason.

For example, a peer-reviewed paper linking the mRNA vaccines with myocarditis, authored by doctors Jessica Rose and Peter McCullough, was suddenly withdrawn with insufficient cause.

Some high-profile scientists have decided that the time burden and logistical intensity of publishing in the major medical journals is simply not worth it.

Carl Heneghan and Tom Jefferson, for example, two of the most reputable researchers in the world, say they’ll only publish in specialised journals that have peer-reviewers with the right expertise. 

Otherwise, the bulk of their work is published on the writing platform, Substack (Trust The Evidence).

“I do worry about that,” says Ioannidis.  “We need the voices of people like Carl Heneghan and Tom Jefferson and others in the mix. I suppose if they’ve been thwarted, then there must be some venue where that missing part can appear, and perhaps Substack caters to that need.”

“I do wish that we get them back into the traditional type of medical journals though. If the classical literature is missing a very key perspective like theirs, then the distortion becomes bigger,” he said.

“It makes it more difficult to balance the literature when knowledgeable, critical voices are missing.  I know I may sound like I’m willing to stick to that sinking ship. But I would prefer to not fragment science into medical journals, and Substack and who knows where else,” added Ioannidis.

Smith on the other hand, is more enthusiastic about self-publishing.

“I’m in favour of getting it out there. Let the world decide. It makes a lot of sense to me,” says Smith citing his own challenges with publishing in medical journals.

“Recently, I submitted a piece to the Lancet – a book review – and there was the hassle of all the forms you have to fill in, all the comments from the editors, which I mean – maybe it’s arrogance on my part – but didn’t seem to make things much better,” said Smith in a perturbed tone.

“You’ve got a particular voice, and they disrupt it to some extent. So, it ends up much messier. Doesn’t feel to me like there’s a lot of value added in that process,” he said.

Smith says self-publishing is more of a problem if you are a junior researcher and want to rise in the academic arena. 

“You need to publish in these journals because that’s how you’re judged. If you’ve published in the New England Journal of Medicine, it’s assumed to be a very significant piece of research. I mean, it’s completely unscientific to use the place you publish as a surrogate for the value of the research, but that’s what continues to happen,” said Smith.

Diminished trust

Redberg says it’s not just medical journals that lost trust.

“I think people’s trust in medicine and public health diminished in general in the last few years. The sad part to me is that science became political – whether you wore a mask or not became a political statement – It’s not a political question. It’s a scientific question,” said Redberg. 

Ioannidis who famously authored the paper, “Why Most Published Research Findings Are False” said, “I think that we are losing…well, we have already lost the trust of a major part of the population.”

“Covid created a lot of extra stress on the system. People wanted to publish papers very quickly, by now it’s almost a million papers. We’ve looked at the covid literature and most of it was very sloppy, corners were cut, probably worse than usual,” said Ioannidis.

“The frontier of science is broken at the moment. If we do not acknowledge that we have a problem – and make no mistake – we have a very serious problem, then it will be difficult to defend against conspiracy theories or against people who just want to make money by spreading misinformation or disinformation,” he added.

So, are medical journals dead?

“I don’t think medical journals are dead, no. I feel like they’re busier and more important than ever, because there’s so much innovation and I think that disseminating it through a high-quality, peer-review process is the best way to go,” said Redberg.

Ioannidis is quick to acknowledge there is a problem with medical journals. “They are very sick, and they suffer from all sorts of diseases, but I just don’t want to say that I’m giving up on them. They need to transform. I hope that they get better. But I don’t want to proclaim them dead yet.”

Smith agrees that there’s a role for medical journals, but he seems less invested. 

“It’s interesting to me in a way that journals are still alive, because I think there’s a lot of reasons why they should be dead,” said Smith.

Kaynak: https://brokenscience.org/are-medical-journals-dead/?utm_source=substack&utm_medium=email

***

Siz de yorumunuzu paylaşın: